Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology

Nutriband Inc. (NASDAQ: NTRB) has achieved a milestone in the pharmaceutical industry by securing U.S. patent No. 12,318,492 for its 'Abuse and Misuse Deterrent Transdermal Systems.' This patent, awarded on June 3, 2025, fortifies the company's intellectual property rights over its Aversa(TM) technology, designed to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure. The technology is central to Nutriband's development of Aversa Fentanyl, poised to become the first abuse-deterrent fentanyl patch available in the market, with potential U.S. sales ranging between $80 million and $200 million.

The significance of this development cannot be overstated, as it represents a critical advancement in addressing the opioid crisis. By integrating Aversa(TM) technology into transdermal patches, Nutriband is at the forefront of creating safer pharmaceutical options that deter abuse while ensuring patients receive the medication they need. This innovation has the potential to significantly impact public health by reducing the availability of abusable drugs, thereby contributing to the broader effort to combat opioid addiction and its devastating consequences.

For the pharmaceutical industry, Nutriband's patent underscores the growing importance of abuse-deterrent technologies in drug development. As regulatory bodies and healthcare providers increasingly prioritize patient safety and drug abuse prevention, technologies like Aversa(TM) are likely to become standard in the formulation of medications with high abuse potential. This patent not only enhances Nutriband's competitive edge but also sets a precedent for future innovations in the field.

The implications of this patent extend beyond the pharmaceutical industry, offering hope for communities ravaged by the opioid epidemic. By providing a tool to prevent abuse and misuse, Nutriband's Aversa(TM) technology could play a pivotal role in saving lives and reducing the societal and economic burdens associated with drug abuse. As the company moves forward with the development of Aversa Fentanyl, the healthcare community and patients alike await the potential benefits of this groundbreaking technology.